



Press  
release

Montpellier (France), September 13, 2018 - 8:00 am CEST

## Intrasense: company news and agenda details

Intrasense (FR0011179886 - ALINS), specialist in medical imaging software solutions and designer of Myrian®, recalls that its 2018 half-year results will be published on September 17 and also provides details about its funding agreement concluded with European High Growth Opportunities Securitization Fund and its proposed merging with DMS Group.

As specified in the [August 28, 2018 press release](#), the setup of a financing line by issuing OCA bond (without attached BSA) signed with the Luxembourg fund, European High Growth Opportunities Securitization Fund, provides a comprehensive financing for its breakeven plan already underway, and for the deployment of its strategy stated in 2018, oriented on B2B sales.

The flexible bond financing line by OCABSA issuing, concluded with Bracknor Fund Ltd on January 12, 2016, has come to an end, as all the bonds have been converted since September 11, 2018.

Intrasense chose to finance its growth through a new line of financing by issuing OCA bond (without attached BSA) including a regular share issue according to the automatic draw-downs under OCA, providing visibility and progressivity to the impact of the OCA share conversions. It is to be noted that after issuance of 1<sup>st</sup> tranche on August 27, 2018, the company is committed to fourteen additional OCA tranches to be issued before the end of commitment period, at the pace of one 125.000 euros tranche every 25 trading days, representing a total nominal amount of 2 million euros. The number of additional new regular shares that will be issued upon conversion of OCA will depend on market price at every OCA conversion request, in accordance with the procedures outlined on the press release published on August 28, 2018.

Intrasense also states that the [proposed merging with DMS Group](#) is still under discussions. This project would enable Intrasense to accelerate its breakeven plan through larger commercial volumes and a facilitated access to key accounts. In the scope of the exclusive negotiations, discussions between the two companies are ongoing about the final agreement and parity, which the boards of directors of both companies will need to approve as soon as finalized, to then proceed to convene shareholders' meetings immediately. A joint press release will provide details about the definitive modalities of the project.

The Intrasense shareholders will be informed of terms and details for this operation as early as possible before the general meeting concerning this



operation. The issue of this capital transaction could occur by the end of 2018, after the vote of the two shareholders' meetings.

In parallel with the 2018 half-year results publication on Monday 17 September, Intrasense reminds that its annual general meeting including the proposed resolutions recently published but excluding the proposed project with DMS, will be taking place on Friday 28 September 2018 in Paris. All documentation regarding to this general meeting is available on the [company website internet](#) in the "General meetings" page.

### About Intrasense

Founded in 2004, Intrasense develops and markets a unique medical device called Myrian®, a software platform that facilitates diagnosis, decision-making and therapeutic follow-up and makes them more secure. Thanks to Myrian®, more than 800 health institutions spread over 40 countries use a unique and integrated platform supporting all types of imaging modalities (MRI, scanner...). Enriched with expert clinical modules dedicated to specific pathologies, Myrian® also provides a universal image treatment solution that can be fully integrated in any health information system. Intrasense includes 40 employees among which 20 are dedicated to Research & Development. Intrasense has been labelled 'innovative company' by the BPI and invested more than 10 million euros in Research & Development since its creation.

More information on [www.intrasense.fr](http://www.intrasense.fr).

### Contacts

Intrasense  
Nicolas Reymond  
Chief Executive Officer  
Montpellier - FRANCE  
Tel: +334 67 130 130  
[investor@intrasense.fr](mailto:investor@intrasense.fr)

NewCap  
Investor Relations and  
Financial Communication  
Valentine Brouchet - Pierre Laurent  
Tel: +331 44 71 94 96  
[intrasense@newcap.eu](mailto:intrasense@newcap.eu)

